Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "RIL"

1250 News Found

Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response
Clinical Trials | November 27, 2025

Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response

Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020


Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech
News | November 27, 2025

Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech

The fresh capital will propel Cordance into its first-in-human clinical trial


Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health
News | November 27, 2025

Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health

Renalyx will continue operating as an independent unit within the group


Zydus inks licensing, commercialisation pact with RK Pharma
News | November 27, 2025

Zydus inks licensing, commercialisation pact with RK Pharma

RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US


Owlet taps OpenSynergy’s bluetooth tech to power next-gen baby monitor
Medical Device | November 27, 2025

Owlet taps OpenSynergy’s bluetooth tech to power next-gen baby monitor

Owlet’s push comes as parents demand smarter, more dependable nursery tech


Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025
R&D | November 25, 2025

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies


Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla
Drug Approval | November 24, 2025

Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla

The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia


Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi
Drug Approval | November 24, 2025

Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi

Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis


Merck’s two-drug HIV regimen hits phase 3 success
Clinical Trials | November 21, 2025

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks